Indivior Pharmaceuticals, Inc. (INDV) Cash Flow Statement
Indivior Pharmaceuticals, Inc. (INDV) generated -$40.0M of operating cash flow over the twelve months to 2026-06-30, spent $71.0M on capital expenditure and had free cash flow of -$111.0M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
INDVIndivior Pharmaceuticals, Inc.Follow INDV — free
—
Price chart with a free account
- Market cap
- 4.1B
- P/E TTM
- 12.4
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -0.30 | 0.04 | -0.03 | -0.04 | |
| Capital expenditure | 0.01 | 0.03 | 0.07 | -0.07 | |
| Free cash flow | -0.31 | 0.01 | -0.09 | -0.11 | |
| Share repurchases | 0.03 | 0.17 | 0.01 | — | |
| Stock-based compensation | 0.02 | 0.02 | 0.03 | — |
USD billions · SEC XBRL
Indivior Pharmaceuticals, Inc. — questions
- What is Indivior Pharmaceuticals, Inc.'s operating cash flow?
- -$40.0M over the twelve months to 2026-06-30.
- How much does Indivior Pharmaceuticals, Inc. spend on capital expenditure?
- $71.0M over the twelve months to 2026-06-30.
- What is Indivior Pharmaceuticals, Inc.'s free cash flow?
- -$111.0M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Indivior Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.